Search results for "biochemistry"

showing 10 items of 20172 documents

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Mul…

2019

Continuous treatment with lenalidomide (R) and dexamethasone (d) is a standard of care for multiple myeloma (MM) patients (pts) not candidates for autologous stem cell transplantation (ASCT). As previously reported, the addition of Clarithromycin (C) to Rd has proven to be safe and effective, and case-control analyses suggested a significant additive value with the combination. C optimizes the therapeutic effect of glucocorticoids by increasing the area under the curve, has immunomodulatory effects and may have direct antineoplastic properties. However, there are not randomized phase III trials confirming these results. GEM-Claridex in an open, randomized, phase III trial for untreated new…

medicine.medical_specialtybusiness.industryImmunologyDisease progressionCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionTransplantationClinical trialAutologous stem-cell transplantationRandomized controlled triallawInternal medicinemedicineIn patientbusinessMultiple myelomaLenalidomidemedicine.drugBlood
researchProduct

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

2016

Abstract Introduction: Temsr (Torisel®) administered at 175 mg IV once weekly for first 3 weeks, followed by 75mg IV once weekly (Temsr 175/75 mg) is approved in the European Union for the treatment of adult patients with relapsed and/or refractory MCL based on an overall positive benefit-risk relationship demonstrated for this treatment regimen in the pivotal phase III study (Hess et al. J Clin Oncol. 2009;27:3822-9). This ongoing phase 4, multicenter, randomized, open-label study was conducted to explore whether similar efficacy can be achieved for the treatment of patients with relapsed/refractory MCL with a Temsr regimen that is expected to yield fewer side effects than the Temsr 175/75…

medicine.medical_specialtybusiness.industryImmunologyEcchymosisHazard ratioCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryRegimenRefractoryInternal medicinemedicineClinical endpointmedia_common.cataloged_instanceMantle cell lymphomamedicine.symptomEuropean unionbusinessmedia_commonBlood
researchProduct

Predictive Value for Increased Factor XIa and Plasma Kallikrein Activity in Acute Venous Thromboembolism

2021

Abstract Venous thromboembolism (VTE) is associated with increased coagulation activity, which in part can be attributed to the contact pathway of coagulation. Evidence from pre-clinical and epidemiological studies suggests that deficiency in factors of contact activation (e.g. coagulation factors (F) XI and FXII) protects against VTE. However, limited information exists regarding the activation of the contact system in the setting of acute VTE. In the current study, patients with confirmed VTE events (n=321) from the VTEval study and controls (n=300) from the population-based PREVENT-it pilot study were included. Plasma samples were collected from patients after confirmed VTE events or con…

medicine.medical_specialtybusiness.industryImmunologyFactor XIaCell BiologyHematologyBiochemistryPredictive valuePlasma kallikrein activityInternal medicinemedicineCardiologycardiovascular diseasesbusinessVenous thromboembolismBlood
researchProduct

AB0715 THE PREVALENCE OF FIBROMIYALGIA IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND THE RELATIONSHIP BETWEEN FATIGUE AND QUALITY OF LIFE

2021

Background:Familial Mediterranean Fever (FMF) can cause various muscle diseases. Because it is a chronic auto inflammatory disease, painful trigger points may be encountered in the examination due to a decrease in the pain threshold (1-3).Objectives:The aim of this study was to determine the prevalence of Fibromiyalgia in patients with FMF, at the same time to identify the relationship between fatigue and quality of life.Methods:Sixtyseven patients (38 female, 29 male) with FMF were enrolled in the study. They were diagnosed with FMF based on the Livneh diagnostic criteria (4). Fibromyalgia involvement of the patients was evaluated according to the Fibromyalgia Impact Questionnaire (FIQ). P…

medicine.medical_specialtybusiness.industryImmunologyFamilial Mediterranean fevermedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyQuality of lifeFibromyalgiaInternal medicineThreshold of painImmunology and AllergyMedicineFamily historybusinessBody mass indexDepression (differential diagnoses)Annals of the Rheumatic Diseases
researchProduct

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial …

2008

Abstract We have previously reported that compared to CHOP alone the addition of Rituximab (R) to CHOP significantly increases the response rate (RR), the time to treatment failure (TTF) and also the overall survival (OS) in patients with newly diagnosed advanced follicular lymphoma. However, in the previous report, the median observation time was short with 18 months and no data were reported on the outcome of different risk groups according to the FLIPI (Hiddemann et al., Blood 2005). We now report on the treatment outcome of 552 patients with advanced stage follicular lymphoma randomized between R-CHOP versus CHOP alone after a median follow up of 58 months. Responding patients < …

medicine.medical_specialtybusiness.industryImmunologyFollicular lymphomaAlpha interferonCell BiologyHematologyCHOPDebulkingmedicine.diseaseBiochemistryChemotherapy regimenGastroenterologySurgerylaw.inventionRandomized controlled trialMedian follow-uplawInternal medicinemedicineRituximabbusinessmedicine.drugBlood
researchProduct

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

2015

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guide IST intensity but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR; defined as no active bleeding, FVIII restored >50 IU/dL, hemostatic treatment stopped >24 hours) was achieved by 83% of patients after a median of 31 days (range 7-362…

medicine.medical_specialtybusiness.industryImmunologyHazard ratioAutoantibodyCell BiologyHematologyOdds ratioBiochemistryGastroenterologyConfidence intervalSurgeryhemic and lymphatic diseasesInternal medicinemedicineAcquired hemophiliaAdverse effectbusinessSurvival analysisCause of deathBlood
researchProduct

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and …

2019

Introduction: The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint is the achievement of bone marrow minimal residual disease (MRD) negativity. However, other methods of disease evaluation in serum such as heavy+light chain (HLC) assessment, with a potential complementary value to the IMWG response criteria, have also been tested. Aim: To evaluate the performance of HLC assay in HRsMM pts at diagnosis and after consolidation, comparing the results with standard serological methods and Next Generation Flow (NGF) for the assessment of bone marrow MRD. Patients and Methods: Ninety HRsMM pts include…

medicine.medical_specialtybusiness.industryImmunologyHigh dose melphalanNegativity effectCell BiologyHematologyStandard methodsmedicine.diseaseBiochemistryMinimal residual diseaseResponse assessmentAssessment dataFamily medicineClinical valueMedicinebusinessMultiple myelomaBlood
researchProduct

THU0573 Association Between Sosiodemogapic Data and Perceived Health Status on Sexual Activity in Patients with Axial Spondyloarthritis

2013

Background Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disorder causing signs and symptoms from the axial skeleton, but may also affect peripheral joints, tendons and internal organs. Ax-SpA may give rise to significant loss of function and impaired quality of life. Despite the known importance of sexuality as part of quality of life (Healey 2009), only a few studies have explored sexuality in ax-SpA patients. Objectives To investigate the association between sosiodemograpic data and perceived health status on sexual activity in patients with ax-SpA. Methods Patients with ax-SpA (fulfilling the axial SpA criteria) were consecutively recruited from one clinic in southern and o…

medicine.medical_specialtybusiness.industryImmunologyHuman sexualityDiseaseAffect (psychology)General Biochemistry Genetics and Molecular BiologyRheumatologyQuality of lifeInternal medicinemedicinePhysical therapyImmunology and AllergyAssociation (psychology)BASFIAdverse effectbusinessBASDAIAnnals of the Rheumatic Diseases
researchProduct